`

Albireo Pharma, Inc

Biotechnology Research

Sign Up to View More
revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$45.0M
size-icon Size
51 - 200
About Us
Org Charts
Employees
Buyer Intent
Tech Stack
Jobs

Frequently Asked Questions About Albireo Pharma, Inc

What does Albireo pharma, inc do?+

On March 2, 2023, Albireo was acquired by Ipsen, strengthening Ipsens rare disease portfolio with promising therapeutics for pediatric and adult rare liver diseases. Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireos lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase...

What is Albireo pharma, inc's industry? +

Albireo pharma, inc operates in the Biotechnology research industry.

What is Albireo pharma, inc's revenue? +

Albireo pharma, inc's revenue is 11m - 100m

What is Albireo pharma, inc's company size? +

Albireo pharma, inc has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Sign Up For Free
Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Sign Up For Free
Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.

Sign Up For Free